Evidence map›Paper›PMID 39412140›Full record

ReviewExpert review of anticancer therapy2024

Future investigative directions for novel therapeutic targets in head and neck cancer.

Jacqueline P Nguyen, Liam C Woerner, Daniel E Johnson, Jennifer R Grandis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of anticancer therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jacqueline P NguyenDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, CA, USA.
Liam C WoernerDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, CA, USA.
Daniel E JohnsonDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, CA, USA.
Jennifer R GrandisDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, CA, USA.

Funding

The Cancer Cell Map Initiative v2.0U54CA274502 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trey Ideker, Nevan J Krogan · 2022 to 2026
$14.2M
Integrating genomics and the protein interactome for HPV+ head and neck cancer therapyR35CA231998 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2018 to 2024
$6.2M
NCI NIH HHS R35 CA231998NCI NIH HHS U54 CA274502
6 · The paper itself

Abstract

areas coveredHere we describe novel agents, their mechanism(s) of action, preclinical results, and ongoing clinical trials in HNSCC. EXPERT OPINION: Established therapeutic targets in HNSCC include EGFR (cetuximab) and PD-1 (pembrolizumab and nivolumab). Despite the detection of many other possible targets in HNSCC cell lines and patient tumors, no other therapies have successfully advanced to date. Identification of predictive biomarkers may guide the use of targeted agents and combination therapies. Clinical trials supported by strong preclinical data in relevant models are more likely to advance treatment options.

Indexed as

Biomarkers, TumorHead and Neck NeoplasmsMolecular Targeted TherapySquamous Cell Carcinoma of Head and NeckAnimalsDrug DevelopmentHumansBiomarkers, Tumorbreakthough designationHNSCCimmunotherapyPI3K inhibitorsradiation therapy

Identifiers

PMID39412140
PMCPMC11514385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.